

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OR TO U.S. PERSONS, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.



Celon Pharma S.A.

(a joint-stock company with its registered office in Kielcin at ul. Ogródowa 2A, 05-092 Łomianki, registered in the registry of entrepreneurs of the National Registry Court under number 0000437778)

Information on the Offer Price of the Offer Shares and the number of the Offer Shares initially allocated based on the book-building process and subscription orders of the Retail Investors („Information”)

This Information has been published in connection with the information contained in the Prospectus of Celon Pharma S.A. with its registered office in Kielcin, approved on 1 July 2021 by the Polish Financial Supervision Authority and it is submitted by the Company to the Polish Financial Supervision Authority and made publicly available in the manner described in Article 21(2) of the Prospectus Regulation, i.e. in the manner in which the Prospectus was published.

Capitalized terms used in this Information have the meaning assigned to them in the Prospectus.

Offer Price for the Offer Shares

The Offer Price for the Offer Shares was determined based on the book-building process among the Institutional Investors pursuant to the terms of agreements entered into between the Issuer and the Banks. The issue price of the Offer Shares was determined by the Management Board on the basis of the authorisation given to the Management Board in the resolution no. 4 of the General Meeting of 16 February 2021.

The Offer Price for the Offer Shares was set at PLN 36.00 (thirty six zlotys) per Offer Share.

The number of Offer Shares initially allocated

The Company, in consultation with the Joint Global Coordinators, decided to determine the number of the Offer Shares initially allocated based on the book-building process and subscription orders of the Retail Investors.

The number of the Offer Shares initially allocated was set at 6,000,000 (six million) Offer Shares.

The number of the Offer Shares initially allocated to the Retail Investors is 185,678 (one hundred eighty-five thousand six hundred seventy-eight), which represents 3.1% of all the Offer Shares.

The number of Offer Shares initially allocated to Institutional Investors is 5,814,322 (five million eight hundred fourteen thousand three hundred twenty-two), representing 96.9% of the total Offer Shares.

This announcement is for information purposes only and will under no circumstances constitute the basis for a decision to invest in the shares of Celon Pharma S.A. (the “Company”) and as such does not constitute or form part of and should not be construed as an offer, solicitation or invitation to sell or issue, or an offer, solicitation or invitation to, subscribe for, underwrite, buy or otherwise acquire securities of the Company or any of its subsidiaries in any jurisdiction, or an inducement/recommendation to enter into investment activity in any jurisdiction. Neither this press release nor any part hereof, nor the fact of its distribution or issuance, shall form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever. The Prospectus prepared in connection with the public offering and admission and introduction of the Company’s securities to trading on the Warsaw Stock Exchange is the sole legally binding document containing information

on the Company and the offering of its securities in Poland (the "Offering"). Any investment in connection with the Offering should be made solely on the basis of the information which is contained in the approved and published Prospectus, the Pricing Statement and any amendments or supplements thereto. The approval of the Prospectus should not be understood as an endorsement of the Company's shares that are being offered within the Offering and that are subject to admission to trading on the regulated market. The Prospectus may contain information that differs from the information contained in this press release. Potential investors should read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the securities referred to in the Prospectus.

The date of admission of the Company's shares to the Warsaw Stock Exchange ("Admission") may be influenced by various circumstances, some of which are beyond our control, including market conditions. There is no guarantee that Admission will occur and you should not base your financial decisions on the Company's intentions in relation to Admission at this stage. Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing all of the amount invested. Persons considering making such investments should consult an authorised person specialising in advising on such investments. This announcement does not constitute a recommendation concerning the Offering. The value of shares can decrease as well as increase. Potential investors should consult a professional advisor as to the suitability of the Offering for the person concerned.

This press release is not for distribution or use by any person or entity in any jurisdiction where such distribution or use would be contrary to local law or regulation or which would subject the Company or any of its affiliates to authorisation, notification, licensing or other registration requirements under applicable laws. Distribution of this press release and other information connected to the Offering may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. It may be unlawful to distribute this press release in certain jurisdictions. This press release is not for distribution in the United States or to U.S. persons, Australia, Canada and Japan. Acquiring securities to which this press release refers may expose an investor to a significant risk of losing all of the amount invested. Persons considering investment should consult an authorised person specialising in advising on such investments. This material does not constitute an investment recommendation within the meaning of the Market Abuse Regulation (Regulation (EU) 596/2014) and of the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing the Market Abuse Regulation with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest, nor does it purport to give legal, tax or financial advice. Statements contained herein may constitute "forward-looking statements". Forward-looking statements are generally identifiable by the use of certain words, including but not limited to: "may", "will", "should", "plan", "expect", "anticipate", "estimate", "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's or its industry's actual financial condition, results of operations or performance to be materially different from any future financial condition, results of operations or performance expressed or implied by such forward-looking statements. In the United Kingdom this press release is being distributed and is directed only at "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) who: (i) have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) are high net worth entities and other persons to whom such communication may otherwise lawfully be made falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as the "Relevant Persons"). This press release must not be acted on or relied on by persons who are not the Relevant Persons. Any investment or investment activity to which this communication relates is available only to the Relevant Persons and will be engaged in only with the Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. The securities will be available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be only with, Relevant Persons. With respect to member states of the European Union other than the United Kingdom, this press release is directed only at, and the securities referred to herein will be offered only to, qualified investors within the meaning of Article 2(e) of the EU Regulation 2017/1129, such persons being referred to as the "Qualified Investors") and/or in other circumstances falling within Article 1 section 4 of the Prospectus Regulation. Any such Qualified Investor will also be deemed to have represented and agreed that any such securities acquired by it in the Offering have not been acquired on behalf of persons other than such Qualified Investors. This press release is not an offer of securities for sale in the United States or to U.S. persons. The securities to which this press release relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States or to U.S. persons absent registration or an exemption from registration or in a transaction not subject to the registration requirements of the Securities Act. There will be no public offering of the securities in the United States. This announcement is not directed at or intended to be

accessible by persons located in the United States (including its territories and possessions, any state of the United States and the District of Columbia) or U.S. persons, other than to "qualified institutional buyers" within the meaning of Rule 144A under the Securities Act or pursuant to another exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.